Iron dysregulation in Huntington's disease.

Muller M, Leavitt BR.

J Neurochem. 2014 Aug;130(3):328-50. doi: 10.1111/jnc.12739. Review.

Huntington's disease is a four-repeat tauopathy with tau nuclear rods.

Fernández-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernández F, Avila J, Lucas JJ.

Nat Med. 2014 Aug;20(8):881-5. doi: 10.1038/nm.3617.

Visual system integrity and cognition in early Huntington's disease.

Wolf RC, Sambataro F, Vasic N, Baldas EM, Ratheiser I, Bernhard Landwehrmeyer G, Depping MS, Thomann PA, Sprengelmeyer R, Süssmuth SD, Orth M.

Eur J Neurosci. 2014 Jul;40(2):2417-26. doi: 10.1111/ejn.12575.

Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.

Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, Volitakis I, Cherny RA, Chopra V, Bush AI, Hersch S, Fox JH.

Neurobiol Dis. 2014 Nov;71:34-42. doi: 10.1016/j.nbd.2014.06.022.

Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Anglada-Huguet M, Xifró X, Giralt A, Zamora-Moratalla A, Martín ED, Alberch J.

Mol Neurobiol. 2014 Apr;49(2):784-95. doi: 10.1007/s12035-013-8556-x.

Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.

Ernst JT, Neubert T, Liu M, Sperry S, Zuccola H, Turnbull A, Fleck B, Kargo W, Woody L, Chiang P, Tran D, Chen W, Snyder P, Alcacio T, Nezami A, Reynolds J, Alvi K, Goulet L, Stamos D.

J Med Chem. 2014 Apr 24;57(8):3382-400. doi: 10.1021/jm500042s.

An update on Huntington's disease: from the gene to the clinic.

Kim SD, Fung VS.

Curr Opin Neurol. 2014 Aug;27(4):477-83. doi: 10.1097/WCO.0000000000000116. Review.

The basal ganglia in perceptual timing: timing performance in Multiple System Atrophy and Huntington's disease.

Cope TE, Grube M, Singh B, Burn DJ, Griffiths TD.

Neuropsychologia. 2014 Jan;52:73-81. doi: 10.1016/j.neuropsychologia.2013.09.039.

CAG-Expansion Haplotype Analysis in a Population with a Low Prevalence of Huntington's Disease.

Pulkes T, Papsing C, Wattanapokayakit S, Mahasirimongkol S.

J Clin Neurol. 2014 Jan;10(1):32-6. doi: 10.3988/jcn.2014.10.1.32.

Modulation at age of onset in tunisian huntington disease patients: implication of new modifier genes.

Hmida-Ben Brahim D, Chourabi M, Ben Amor S, Harrabi I, Trabelsi S, Haddaji-Mastouri M, Gribaa M, Sassi S, Gahbiche FE, Lamouchi T, Mougou-Zereli S, Ben Ammou S, Saad A.

Genet Res Int. 2014;2014:210418. doi: 10.1155/2014/210418.

Differential diagnosis of Huntington's disease: what the clinician should know.

Cardoso F.

Neurodegener Dis Manag. 2014;4(1):67-72. doi: 10.2217/nmt.13.78.

Do glial cells play an anti-oxidative role in Huntington's disease?

Gao Y, Chu SF, Li JP, Zuo W, Wen ZL, He WB, Yan JQ, Chen NH.

Free Radic Res. 2014 Oct;48(10):1135-44. doi: 10.3109/10715762.2014.936432. Review.

STIM1 Protein Activates Store-Operated Calcium Channels in Cellular Model of Huntington's Disease.

Vigont VA, Zimina OA, Glushankova LN, Kolobkova JA, Ryazantseva MA, Mozhayeva GN, Kaznacheyeva EV.

Acta Naturae. 2014 Oct;6(4):40-7.

First case with Huntington's disease in The Gambia.

Almaguer-Mederos LE, Vega Abascal J, Ramos Cabrera A, García Quilez F, Betancourt Álvarez P, Miranda Rosales F, Ferriol Ramírez A, Khalil MI, de Jorge López L, Volpini V, Nyan O.

J Neurol Sci. 2014 Mar 15;338(1-2):238-40. doi: 10.1016/j.jns.2013.12.045. No abstract available.

In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington's disease.

Müller S.

Transl Neurodegener. 2014 Aug 18;3:17. doi: 10.1186/2047-9158-3-17.